Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile. OBJECTIVE: The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets. DESIGN AND SETTING: We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers. PATIENTS: The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM). INTERVENTION: The same daily dose of hydrocortisone was administered as OD dual-release or TID. MAIN OUTCOME MEASURE: We evaluated cortisol pharmacokinetics. RESULTS: Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7 kg, P = 0.005), systolic blood pressure (difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004). CONCLUSION: The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, whereas this dual-release hydrocortisone preparation was shown to slightly reduce blood pressure and HbA1c (104), such results may not always be desirable in patients with PAI.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“Dual and slowrelease formulations of cortisol may better mimic circadian hormone release (104) but do not mimic the physiological pulsatile release of cortisol.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“In men with CAH, gonadal and reproductive function are often impaired due to primary gonadal failure from TARTs and/or secondary gonadal failure due to suppressed hypothalamicpituitary-gonadal axis as a consequence of high adrenal androgen concentrations (378,437,438,625).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“The reported prevalence of TARTs in CAH ranges from 14% to 86% (437,634), with an average of 25% in adolescents, and 46% in men (378).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“TARTs are benign testicular tumors typically found in males with classic CAH (378,437).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Self-citationVgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Mastorakos, G., Vela-Bueno, A., Kales, A., & Chrousos, G. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7778 · Cited by 884 · cited 1×
“When targeting a physiological S-cortisol profile, it should also be considered that although collection of normative data has been done with care (27), there is still a concern that nighttime cortisol levels might be falsely high due to an arousal effect (stress) (28).”
(1984) · Medical Entomology and Zoology · Cited by 741
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 2×
“Studies in patients with AD have shown a more than double the standardized mortality rate (4, 5) despite contemporary optimal glucocorticoid replacement therapy.”
Self-citationRossi, R. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1440 · Cited by 419 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Hahner, S., Loeffler, M., Bleicken, B., Drechsler, C., Milovanovic, D., Fassnacht, M., Ventz, M., Quinkler, M., & Allolio, B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0884 · Cited by 346 · cited 2×
“This may be higher than reported in a previous cross-sectional survey (10) studying the frequency of adrenal crises only.”
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 7×
“Oral hydrocortisone in daily divided doses is the most widely used glucocorticoid in cortisol replacement therapy (2, 3), but no formal studies of its safety and efficacy have been performed in patients with AI.”
InfluentialSelf-citation
Cited by
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
“Dual and slowrelease formulations of cortisol may better mimic circadian hormone release (104) but do not mimic the physiological pulsatile release of cortisol.”
BackgroundInfluentialHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Circadian clocks and insulin resistance
Stenvers, D. J., Scheer, F. A. J. L., Schrauwen, P., la Fleur, S. E., & Kalsbeek, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0122-1 · Cited by 733
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548
“tisone, in addition to a very likely long-term improvement of medication adherence, enabled a closer approximation of the normal daytime cortisol secretory profile, as shown in Figure 14B (415, 416).”
Husebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00136-7 · Cited by 378
Higham, C. E., Johannsson, G., & Shalet, S. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30053-8 · Cited by 267
Self-citationExtensive expertise in endocrinology: adrenal crisis
Allolio, B. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0824 · Cited by 251
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Isidori, A. M., Venneri, M. A., Graziadio, C., Simeoli, C., Fiore, D., Hasenmajer, V., Sbardella, E., Gianfrilli, D., Pozza, C., Pasqualetti, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30398-4 · Cited by 211
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
Husebye, E. S., Castinetti, F., Criseno, S., Curigliano, G., Decallonne, B., Fleseriu, M., Higham, C. E., Lupi, I., Paschou, S. A., Toth, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0689 · Cited by 192
Oussaada, S. M., van Galen, K. A., Cooiman, M. I., Kleinendorst, L., Hazebroek, E. J., van Haelst, M. M., ter Horst, K. W., & Serlie, M. J. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.012 · Cited by 180
Mallappa, A., Sinaii, N., Kumar, P., Whitaker, M. J., Daley, L.-A., Digweed, D., Eckland, D. J. A., Van Ryzin, C., Nieman, L. K., Arlt, W., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3809 · Cited by 167
“morning cortisol levels prior to awakening (33).”
Nicolaides, N. C., Charmandari, E., Kino, T., & Chrousos, G. P. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00070 · Cited by 145
“Recent advances in the therapeutic manipulation of adrenal insufficiency have shown that a dual-release hydrocortisone formulation, which resembles circadian cortisol secretion, results in improved quality of life, decreased body weight and blood pressure, and improved glucose tolerance (124, 125).”
BackgroundSleep and circadian regulation of cortisol: A short review
O'Byrne, N. A., Yuen, F., Butt, W. Z., & Liu, P. Y. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.03.011 · Cited by 145
Epidemiology, pathogenesis, and diagnosis of Addison’s disease in adults
Betterle, C., Presotto, F., & Furmaniak, J. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01079-6 · Cited by 161
“In England, 58% of patients with AAD had associated hypothyroidism, 29% pernicious anemia, and 10% DM-1 [27].”
BackgroundInfluentialQuinkler, M., Miodini Nilsen, R., Zopf, K., Ventz, M., & Øksnes, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1114 · Cited by 126
Dahlgren, D., Roos, C., Sjögren, E., & Lennernäs, H. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24258 · Cited by 139
Self-citationAdrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy
Johannsson, G., Falorni, A., Skrtic, S., Lennernäs, H., Quinkler, M., Monson, J. P., & Stewart, P. M. (2015) · Clinical Endocrinology · doi:10.1111/cen.12603 · Cited by 122
Self-citationWhitaker, M. J., Debono, M., Huatan, H., Merke, D. P., Arlt, W., & Ross, R. J. (2014) · Clinical Endocrinology · doi:10.1111/cen.12316 · Cited by 121
Adrenal insufficiency – recognition and management
Pazderska, A., & Pearce, S. H. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-258 · Cited by 121
Grossman, A., Johannsson, G., Quinkler, M., & Zelissen, P. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0450 · Cited by 119
Self-citationAdrenal Clocks and the Role of Adrenal Hormones in the Regulation of Circadian Physiology
Leliavski, A., Dumbell, R., Ott, V., & Oster, H. (2015) · Journal of Biological Rhythms · doi:10.1177/0748730414553971 · Cited by 118
“An oral dual-release HC preparation is being tested in the treatment of adrenal insufficiency (Lovas and Husebye, 2007; Johannsson et al., 2009; Johannsson et al., 2012).”
BackgroundFleseriu, M., Christ‐Crain, M., Langlois, F., Gadelha, M. R., & Melmed, S. K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00342-8 · Cited by 141
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
An Update on Addison’s Disease
Barthel, A., Benker, G., Berens, K., Diederich, S., Manfras, B. J., Grüber, M., Kanczkowski, W., Kline, G. A., Kamvissi, V., Hahner, S., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0804-2715 · Cited by 135
“In order to improve the pharmacokinetic properties and to better provide circadian cortisol concentrations with a morning peak, a dual-release preparation of hydrocortisone that needs to be given as a single oral dose in the morning has been developed [65].”
BackgroundForss, M., Batcheller, G., Skrtic, S., & Johannsson, G. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-8 · Cited by 109
Self-citationYanase, T., Tajima, T., Katabami, T., Iwasaki, Y., Tanahashi, Y., Sugawara, A., Hasegawa, T., Mune, T., Oki, Y., Nakagawa, Y., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0242 · Cited by 104
Regional intestinal drug permeation: Biopharmaceutics and drug development
Lennernäs, H. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.025 · Cited by 103
Self-citationvan Haalen, F. M., Broersen, L. H. A., Jorgensen, J. O., Pereira, A. M., & Dekkers, O. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0556 · Cited by 103
Giordano, R., Guaraldi, F., Marinazzo, E., Fumarola, F., Rampino, A., Berardelli, R., Karamouzis, I., Lucchiari, M., Manetta, T., Mengozzi, G., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0681-z · Cited by 105
“To date, a single phase II multicenter study has assessed the effect of Plenadren on metabolic parameters and HRQoL in patients with AD.”
InfluentialMazziotti, G., Formenti, A. M., Frara, S., Roca, E., Mortini, P., Berruti, A., & Giustina, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0154 · Cited by 96
Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development
Lennernäs, H. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4003392 · Cited by 92
Self-citationGagliardi, L., Nenke, M. A., Thynne, T. R. J., von der Borch, J., Rankin, W. A., Henley, D. E., Sorbello, J., Inder, W. J., & Torpy, D. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2433 · Cited by 85
Monogenic disorders of adrenal steroidogenesis
Baranowski, E. S., Arlt, W., & Idkowiak, J. (2018) · Hormone Research in Paediatrics · doi:10.1159/000488034 · Cited by 79
Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis
(MTG1), O. B. O. E. E., Nowotny, H. F., Ahmed, S. F., Bensing, S., Beun, J. G., Brösamle, M., Chifu, I. O., der Grinten, H. L. C., Clemente, M., Falhammar, H., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02649-6 · Cited by 104
Venneri, M. A., Hasenmajer, V., Fiore, D., Sbardella, E., Pofi, R., Graziadio, C., Gianfrilli, D., Pivonello, C., Negri, M., Naro, F., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00346 · Cited by 80
Primary adrenal insufficiency in children: Diagnosis and management
Kırkgöz, T., & Güran, T. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.05.010 · Cited by 90
Central adrenal insufficiency in children and adolescents
Patti, G., Guzzeti, C., Di Iorgi, N., Maria Allegri, A. E., Napoli, F., Loche, S., & Maghnie, M. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.012 · Cited by 75
Human studies on hypothalamo-pituitary-adrenal (HPA) axis
Liyanarachchi, K., Ross, R. J. M., & Debono, M. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.10.011 · Cited by 98
Tiemensma, J., Andela, C. D., Kaptein, A. A., Romijn, J. A., van der Mast, R. C., Biermasz, N. R., & Pereira, A. M. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0023 · Cited by 73
Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy
Minnetti, M., Hasenmajer, V., Pofi, R., Venneri, M. A., Alexandraki, K. I., & Isidori, A. M. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0066 · Cited by 70
Glucocorticoid Therapy and Adrenal Suppression
Nicolaides, N. C., Pavlaki, A. N., Alexandra, M. A. M., & Chrousos, G. P. (2011) · Europe PMC (PubMed Central) · Cited by 71
Bensing, S., Hulting, A.-L., Husebye, E. S., Kämpe, O., & Løvås, K. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1242 · Cited by 67
Jones, C. M., Mallappa, A., Reisch, N., Nikolaou, N., Krone, N., Hughes, B. A., O’Neil, D. M., Whitaker, M. J., Tomlinson, J. W., Storbeck, K.-H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2855 · Cited by 74
“” An alternative modified-release formulation of hydrocortisone, Plenadren, has immediateand delayed-release actions but is licensed for use in adrenal insufficiency, where it is taken first thing in the morning as a once-daily medication (23), and was not studied here.”
BackgroundAdrenal Cortical Insufficiency
Quinkler, M. O., Beuschlein, F., Hahner, S., Meyer, G., Schöfl, C., & Stalla, G. K. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0882 · Cited by 82
Murray, R. D., Ekman, B., Uddin, S., Marelli, C., Quinkler, M., Zelissen, P. M. J., & the EU-AIR Investigators (2017) · Clinical Endocrinology · doi:10.1111/cen.13267 · Cited by 60
“Additionally, patients receiving modified-release hydrocortisone were excluded, as this subcohort predominantly comprised patients from the pivotal study of efficacy of this formulation, 10 and therefore were unlikely to be receiving treat-ment representative of current clinical practice.”
BackgroundSelf-citationPrimary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy
Esposito, D., Pasquali, D., & Johannsson, G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01928 · Cited by 59
“Supraphysiological doses of GCs increase the prevalence of risk factors for cardiovascular disease (49, 50).”
BackgroundSelf-citationWebb, E. A., & Krone, N. P. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.04.002 · Cited by 72
“A further dual-release hydrocortisone preparation, Pl enadren (Duocort/ViroPharma, Helsingborg, Sweden), has been trialled in patients wi h adrenal insufficiency as once-daily dosing, compared to thrice-daily dosing (104,105).”
BackgroundPituitary Physiology and Diagnostic Evaluation
Melmed, S. K., Kleinberg, D. L., & Ho, K. K. Y. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00008-0 · Cited by 64
Petersons, C. J., Mangelsdorf, B. L., Thompson, C. H., & Burt, M. G. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4305 · Cited by 54
Therapy of adrenal insufficiency: an update
Falorni, A., Minarelli, V., & Morelli, S. (2012) · Endocrine · doi:10.1007/s12020-012-9835-4 · Cited by 61
Bachelot, A., Grouthier, V., Courtillot, C., Dulon, J., & Touraine, P. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0888 · Cited by 57
Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency
Oprea, A., Bonnet, N., Pollé, O. G., & Lysy, P. A. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818821294 · Cited by 68
Kumar, R., & Wassif, W. (2022) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207895 · Cited by 69
Saverino, S., & Falorni, A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101379 · Cited by 66
Pofi, R., Prete, A., Thornton-Jones, V., Bryce, J., Ali, S. R., Faisal Ahmed, S., Balsamo, A., Baronio, F., Cannuccia, A., Guven, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz055 · Cited by 53
“141 However, much attention has focused mainly on optimization of GC replacement in AI (9-11): so 142 far only a few, small studies have investigated MC replacement in patients with primary AI (12).”
BackgroundRagnarsson, O., & Johannsson, G. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0534 · Cited by 51
Self-citationThe Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Is physiological glucocorticoid replacement important in children?
Porter, J., Blair, J., & Ross, R. J. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-309538 · Cited by 50
Werumeus Buning, J., van Faassen, M., Brummelman, P., Dullaart, R. P. F., van den Berg, G., van der Klauw, M. M., Kerstens, M. N., Stegeman, C. A., Muller Kobold, A. C., Kema, I. P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2216 · Cited by 50
Subcutaneous pulsatile glucocorticoid replacement therapy
Russell, G. M., Durant, C., Ataya, A., Papastathi, C., Bhake, R., Woltersdorf, W., & Lightman, S. (2014) · Clinical Endocrinology · doi:10.1111/cen.12470 · Cited by 49
Nilsson, A. G., Marelli, C., Fitts, D., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0327 · Cited by 49
Self-citationCentral adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment
Ceccato, F., & Scaroni, C. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0824 · Cited by 49
The diagnosis and treatment of adrenal insufficiency during childhood and adolescence
Park, J., Didi, M., & Blair, J. (2016) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-308799 · Cited by 47
Hypertension in children with congenital adrenal hyperplasia
Maccabee‐Ryaboy, N., Thomas, W., Kyllo, J., Lteif, A., Petryk, A., Gonzalez‐Bolanos, M. T., Hindmarsh, P. C., & Sarafoglou, K. (2016) · Clinical Endocrinology · doi:10.1111/cen.13086 · Cited by 47
Ragnarsson, O., Mattsson, A. F., Monson, J. P., Filipsson Nyström, H., Åkerblad, A.-C., Kołtowska-Häggström, M., & Johannsson, G. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0397 · Cited by 46
Self-citationMallappa, A., Nella, A. A., Sinaii, N., Rao, H., Gounden, V., Perritt, A. F., Kumar, P., Ling, A., Liu, C., Soldin, S. J., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13813 · Cited by 45
Quality of life in patients with adrenal disease: A systematic review
Ho, W., & Druce, M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13719 · Cited by 44
On behalf of the Italian Society of Endocrinology, Isidori, A. M., Arnaldi, G., Boscaro, M., Falorni, A., Giordano, C. S. D. S., Giordano, R., Pivonello, R., Pozza, C., Sbardella, E., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01146-y · Cited by 50
“2 Schematic representation of cortisol concentrations following hydrocortisone 20–40 mg three times daily in AI patients (HC TID), Plenadren 20–40 mg in AI patients (OD PLEN) [49] and Chronocort 20 mg 11:00 p.”
BackgroundMethodInfluentialNapier, C., & Pearce, S. H. S. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.09.010 · Cited by 51
“It’s place in management remains to be established, although the potential for once daily dosing may be a key advantage [55].”
BackgroundBjörnsdottir, S., Øksnes, M., Isaksson, M., Methlie, P., Nilsen, R. M., Hustad, S., Kämpe, O., Hulting, A., Husebye, E. S., Løvås, K., et al. (2015) · Clinical Endocrinology · doi:10.1111/cen.12670 · Cited by 43
Smith, D. J. F., Prabhudev, H., Choudhury, S., & Meeran, K. M. (2017) · Endocrine Connections · doi:10.1530/ec-17-0257 · Cited by 49
Novel Insight into Etiology, Diagnosis and Management of Primary Adrenal Insufficiency
Malikova, J., & Flück, C. E. (2014) · Hormone Research in Paediatrics · doi:10.1159/000363107 · Cited by 40
Tsuneki, H., Wada, T., & Sasaoka, T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.010 · Cited by 45
Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Ragnarsson, O., Skrtic, S., Wahlberg, J., Achenbach, H., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0067 · Cited by 38
“…randomized, controlled, two-way crossover, clinical trial conducted in patients with primary AI showed that DR-HC treatment was associated with significant improvements in cardiometabolic factors and QoL compared with conventional hydrocortisone tablets administered three times per day (TID) (22).”
InfluentialSelf-citationPituitary Physiology and Diagnostic Evaluation
Kaiser, U. B., & Ho, K. K. Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00008-3 · Cited by 49
Rhythms in cortisol mediate sleep and circadian impacts on health
Liu, P. Y. (2024) · SLEEP · doi:10.1093/sleep/zsae151 · Cited by 43
“…delivery that replicates the proper diurnal slope provides additional metabolic benefits (optimized weight, blood pressure, and glucose metabolism) than delivery which results in a flatter diurnal slope, even when the total dose of cortisol delivered is identical under the two conditions [16, 17].”
BackgroundIncreased Cardiovascular Risk in Patients with Adrenal Insufficiency: A Short Review
Rahvar, A., Haas, C. S., Danneberg, S., & Harbeck, B. (2017) · BioMed Research International · doi:10.1155/2017/3691913 · Cited by 42
“years, a once-daily oral HC dual-release tablet was developed [12].”
BackgroundBone safety of dual-release hydrocortisone in patients with hypopituitarism
Frara, S., Chiloiro, S., Porcelli, T., Giampietro, A., Mazziotti, G., Marinis, L. D., & Giustina, A. (2018) · Endocrine · doi:10.1007/s12020-017-1512-1 · Cited by 40
Metabolic Syndrome in Hypopituitarism
Miljić, D., & POPOVIC, V. M. (2018) · Frontiers of hormone research · doi:10.1159/000485997 · Cited by 42
Approach to the Patient With Glucocorticoid-induced Adrenal Insufficiency
Borresen, S. W., Klose, M., Glintborg, D., Watt, T., Andersen, M., & Feldt‐Rasmussen, U. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac151 · Cited by 47
Reisch, N. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0820-2085 · Cited by 36
“Blood glucose and body weight seem to improve with a more physiologic circadian cortisol day profile reducing the glucocorticoid exposure in particular in the afternoon by about 20 % [41].”
BackgroundGan, E. H., MacArthur, K., Mitchell, A. L., Hughes, B. A., Perros, P., Ball, S. G., James, R. A., Quinton, R., Chen, S., Furmaniak, J., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2449 · Cited by 36
Adrenal insufficiency in pregnancy: challenging issues in diagnosis and management
Yuen, K. C. J., Chong, L. E., & Koch, C. A. (2013) · Endocrine · doi:10.1007/s12020-013-9893-2 · Cited by 42
Sleep, cognition and cortisol in addison’s disease: a mechanistic relationship
Henry, M., Thomas, K. G. F., & Ross, I. L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694046 · Cited by 34
Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids
Williams, E. L., Choudhury, S., Tan, T., & Meeran, K. M. (2016) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.020206 · Cited by 37
“(9) also found a decided patient preference for once-daily regimens vs thrice-daily regimens.”
InfluentialAssessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency
Ceccato, F., Albiger, N., Reimondo, G., Frigo, A. C., Ferasin, S., Occhi, G., Mantero, F., Terzolo, M., & Scaroni, C. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0534 · Cited by 35
“The modern once-daily HC dual-release tablet probably achieved a cortisol profile more similar to healthy subjects, but there is less evidence and was found only in primary AI patients treated with this therapy (31).”
Hypoglycaemia in adrenal insufficiency
Lee, S. C., Baranowski, E. S., Sakremath, R., Saraff, V., & Mohamed, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1198519 · Cited by 42
Optimal glucocorticoid replacement in adrenal insufficiency
Øksnes, M., Ross, R. J. M., & Løvås, K. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.009 · Cited by 35
Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life
Mongioì, L. M., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2017) · Endocrine Connections · doi:10.1530/ec-17-0368 · Cited by 33
Ekman, B., Fitts, D., Marelli, C., Murray, R. D., Quinkler, M., & Zelissen, P. M. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-40 · Cited by 31
“Results of a prospective randomized trial have shown that once-daily treatment with modified-release hydrocortisone provides a sustained serum cortisol concentration for the first 4 hours after the morning dose, followed by a steady reduction, which more closely approximates to the physiological plasma profile than is…”
BackgroundInfluentialSelf-citationLatest Insights on the Etiology and Management of Primary Adrenal Insufficiency in Children
Güran, T. (2018) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.2017.s002 · Cited by 34
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency
Guarnotta, V., Stefano, C. D., Santoro, A., Ciresi, A., Coppola, A., & Giordano, C. S. D. S. (2019) · Endocrine Connections · doi:10.1530/ec-19-0176 · Cited by 35
Borresen, S. W., Thorgrimsen, T. B., Jensen, B., Hilsted, L., Bartels, E. M., Feldt‐Rasmussen, U., & Locht, H. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa011 · Cited by 31
Cardiovascular and Metabolic Impact of Glucocorticoid Replacement Therapy
Johannsson, G., & Ragnarsson, Ó. (2014) · Frontiers of hormone research · doi:10.1159/000360556 · Cited by 36
Self-citationSarafoglou, K., Zimmerman, C. L., Gonzalez‐Bolanos, M. T., Willis, B. A., & Brundage, R. C. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000121 · Cited by 32
“Studies in adults with adrenal insufficiency that used glucocorticoid therapy regimens that provide more circadian-based cortisol concentration time profiles were associated with improvement of body weight, HbA1c, blood pressure, and bone formation markers.(24,25) In comparison, other studies where hydrocortisone dose…”
Novel treatment strategies in congenital adrenal hyperplasia
Turcu, A. F., & Auchus, R. J. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000256 · Cited by 30
“This dual-release hydrocortisone at 30 mg/day achieved improved body weight, glucose metabolism, and both systolic blood pressure and diastolic blood pressure, compared with the similar total daily hydrocortisone, administered in three divided doses, after 3 months of treatment [18].”
Background
Metadata
- Authors
- Johannsson, G., Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., Ryberg, M., Wahlberg, J., Biller, B. M. K., Monson, J. P., Stewart, P. M., Lennernäs, H., & Skrtic, S.
- Affiliations
- University of Gothenburg (SE)
- Skåne University Hospital (SE)
- Umeå University (SE)
- Linköping University (SE)
- Uppsala University Hospital (SE)
- Harvard University (US)
- St Bartholomew's Hospital (GB)
- University of Birmingham (GB)
- Uppsala University (SE)
- Corresponding author
- Johannsson, G.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-02
- Volume
- 97
- Issue
- 2
- Pages
- 473-481
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2108430953
- Semantic Scholar
- 89ffc7ce5ac189e54ea0a893bc1b71924fce41b3
- Cited by
- 329
- References
- 30
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 22 · 2023: 18 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 22 · 2018: 34 · 2017: 25 · 2016: 33 · 2015: 14 · 2014: 33 · 2013: 20 · 2012: 10
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- green
- lup.lub.lu.se
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Forskningsrådet i Sydöstra Sverige
- National Institute for Health and Care Research (NF-SI-0508-10356)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- adrenal insufficiency, cortisol, once-daily dosing, HbA1c, glucose metabolism, diabetes mellitus, blood pressure, body weight, sustained-release tablets
- MeSH terms
- Adrenal Insufficiency, Adult, Aged, Chemistry, Pharmaceutical, Delayed-Action Preparations, Female, Humans, Hydrocortisone, Male, Middle Aged, Time Factors, Treatment Outcome, Cross-Over Studies, Area Under Curve, Metabolome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.